J Kaukua1, T Pekkarinen, T Sane, P Mustajoki. 1. Helsinki University Central Hospital, Peijas Hospital, Department of Internal Medicine, Vantaa, Finland. jarmo.Kaukua@dlc.fi
Abstract
OBJECTIVE: To study health-related quality of life responses to marked weight loss in WHO Class II-III (body mass index (BMI) > or = 35 kg/m2) obese men. DESIGN: An 8 month randomised clinical trial with a 4 month weight loss programme (10 weeks on a very-low-energy diet (VLED) and 17 behaviour modification visits) in the treatment group and no intervention in the control group. SUBJECTS:Nineteen men (mean age 45.9 y, mean BMI 39.3 kg/m2) in the treatment group and 19 men (47.2 y, 39.4 kg/m2) in the control group. MEASUREMENTS: Weight and questionnaires measuring health-related quality of life (RAND 36-Item Health Survey 1.0 and obesity-related psychosocial problems scale). RESULTS: In the treatment group, the mean (s.d.) weight loss was 17.0 (7.4)% at the end of the 4 month therapy. At the end of follow-up, nearly 6 months after the end of VLED in the treatment group, the average maintained weight loss was 13.9 (7.8)% of baseline weight. The control group was weight stable throughout the study. During treatment, there was only transient improvement in general health, bodily pain, mental health, emotional role functioning and vitality (all increases in the scores were not statistically significant). Improvements in physical functioning, social functioning and obesity-related psychosocial problems were maintained until the end of follow-up. The treatment group also reported improvement in perceived health in the past year. There was only minor fluctuation in questionnaire scores in the control group. CONCLUSION: The short-term and maintained health-related quality of life effects of weight loss may differ. Marked weight loss in WHO Class II-III obese men leads to improvements in physical functioning, social functioning, obesity-related psychosocial problems, and perceived health; these improvements were maintained at 4 month post-intervention follow-up.
RCT Entities:
OBJECTIVE: To study health-related quality of life responses to marked weight loss in WHO Class II-III (body mass index (BMI) > or = 35 kg/m2) obesemen. DESIGN: An 8 month randomised clinical trial with a 4 month weight loss programme (10 weeks on a very-low-energy diet (VLED) and 17 behaviour modification visits) in the treatment group and no intervention in the control group. SUBJECTS: Nineteen men (mean age 45.9 y, mean BMI 39.3 kg/m2) in the treatment group and 19 men (47.2 y, 39.4 kg/m2) in the control group. MEASUREMENTS: Weight and questionnaires measuring health-related quality of life (RAND 36-Item Health Survey 1.0 and obesity-related psychosocial problems scale). RESULTS: In the treatment group, the mean (s.d.) weight loss was 17.0 (7.4)% at the end of the 4 month therapy. At the end of follow-up, nearly 6 months after the end of VLED in the treatment group, the average maintained weight loss was 13.9 (7.8)% of baseline weight. The control group was weight stable throughout the study. During treatment, there was only transient improvement in general health, bodily pain, mental health, emotional role functioning and vitality (all increases in the scores were not statistically significant). Improvements in physical functioning, social functioning and obesity-related psychosocial problems were maintained until the end of follow-up. The treatment group also reported improvement in perceived health in the past year. There was only minor fluctuation in questionnaire scores in the control group. CONCLUSION: The short-term and maintained health-related quality of life effects of weight loss may differ. Marked weight loss in WHO Class II-III obesemen leads to improvements in physical functioning, social functioning, obesity-related psychosocial problems, and perceived health; these improvements were maintained at 4 month post-intervention follow-up.
Authors: Amaia Bilbao; Javier Mar; Blanca Mar; Arantzazu Arrospide; Gabriel Martínez de Aragón; José María Quintana Journal: Obes Surg Date: 2009-01-27 Impact factor: 4.129
Authors: Michael D Jensen; Donna H Ryan; Caroline M Apovian; Jamy D Ard; Anthony G Comuzzie; Karen A Donato; Frank B Hu; Van S Hubbard; John M Jakicic; Robert F Kushner; Catherine M Loria; Barbara E Millen; Cathy A Nonas; F Xavier Pi-Sunyer; June Stevens; Victor J Stevens; Thomas A Wadden; Bruce M Wolfe; Susan Z Yanovski; Harmon S Jordan; Karima A Kendall; Linda J Lux; Roycelynn Mentor-Marcel; Laura C Morgan; Michael G Trisolini; Janusz Wnek; Jeffrey L Anderson; Jonathan L Halperin; Nancy M Albert; Biykem Bozkurt; Ralph G Brindis; Lesley H Curtis; David DeMets; Judith S Hochman; Richard J Kovacs; E Magnus Ohman; Susan J Pressler; Frank W Sellke; Win-Kuang Shen; Sidney C Smith; Gordon F Tomaselli Journal: Circulation Date: 2013-11-12 Impact factor: 29.690
Authors: Tyler B Mason; Ross D Crosby; Ronette L Kolotkin; Carlos M Grilo; James E Mitchell; Stephen A Wonderlich; Scott J Crow; Carol B Peterson Journal: Eat Behav Date: 2017-08-18
Authors: William S Yancy; Daniel Almirall; Matthew L Maciejewski; Ronette L Kolotkin; Jennifer R McDuffie; Eric C Westman Journal: Qual Life Res Date: 2009-02-11 Impact factor: 4.147
Authors: Annemieke M A van Nunen; Eveline J M Wouters; Ad J J M Vingerhoets; Joop J Hox; Rinie Geenen Journal: Obes Surg Date: 2007-10 Impact factor: 4.129
Authors: Mara Cristina Lofrano-Prado; Hanna Karen Moreira Antunes; Wagner Luiz do Prado; Aline de Piano; Danielle Arisa Caranti; Lian Tock; June Carnier; Sergio Tufik; Marco Túlio de Mello; Ana R Dâmaso Journal: Health Qual Life Outcomes Date: 2009-07-03 Impact factor: 3.186
Authors: Ronette L Kolotkin; Josephine M Norquist; Ross D Crosby; Shailaja Suryawanshi; Pedro J Teixeira; Steven B Heymsfield; Ngozi Erondu; Allison M Nguyen Journal: Health Qual Life Outcomes Date: 2009-06-09 Impact factor: 3.186